Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: phoenix_rising who wrote (1416)	8/10/2015 7:11:42 AM
From: OldBoar	Read Replies (2) \| Respond to of 2026

Vitaros Now Approved in Twenty-Two Countries in Europe Under the Decentralized ProcedureSAN DIEGO, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that VitarosÂ®, a topical cream indicated for the treatment of patients with erectile dysfunction ("ED"), has been approved through the European Decentralized Procedure ("DCP") in twelve additional countries. Those countries are: Austria, Cyprus, the Czech Republic, Denmark, Finland, Greece, Iceland, Norway, Poland, Portugal, Romania and the Slovak Republic. Apricus' commercialization partners that hold the license for these additional territories will be responsible for the next step of obtaining national phase approvals in order to make Vitaros ready to launch.